Nectar Lifesciences share price & results
- Jun 2026
- Jun 2026
Punjab-based manufacturer of cephalosporin active pharmaceutical ingredients (APIs), finished-dosage formulations and empty hard gelatin capsules, exporting to 45+ countries.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.00 | −100.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -6198.0 | −6182.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -15.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Return on equity | -9.49 | −20.1 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | −4.1 pts | Fiscal year | FY ending Mar 2026 | Not in the analysed materials. No older figure is substituted. | |
| Revenue growth (YoY) | -81.82 | −98.9 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −22.7% 1Y
1Y: ₹13.62 on 24 Oct 2025 → ₹10.53. High ₹22.25 (23 Dec 2025), low ₹9.3 (30 Mar 2026).
- Previous close
- ₹10.46
- Market cap
- ₹202 Cr
- 52-week range
- ₹9.3 – ₹22.25
- One year
- −26.36%
- Return on equity (TTM to Jun 2026)
- -9.49%
Overview
- Symbol
- NSE:NECLIFE
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Nectar Lifesciences Limited does
Based on the company's own presentations, annual report and earnings calls.
Nectar Lifesciences manufactures active pharmaceutical ingredients (APIs) and finished dosage formulations (tablets, capsules, injectables and dry syrups) for cephalosporin and non-cephalosporin antibiotics, alongside empty hard gelatin capsules. Manufacturing runs across two API units in Derabassi, Punjab and a formulation plus capsule unit cluster in Barotiwala, Himachal Pradesh, with several facilities holding approvals from regulators including USFDA, EU-GMP, Japan's PMDA and Korea's KFDA. The company sells domestically and exports to more than 45 countries, with expanding focus on regulated markets such as Europe, Japan, Korea and China. In July 2025 (after FY25 year-end), the board approved a slump sale of the company's API/formulations business to Ceph Lifesciences Private Limited, along with a separate sale of its menthol business assets.
Segments
- Active Pharmaceutical Ingredients (API)
- Finished Dosage Forms (FDF)
- Empty Hard Gelatin Capsules
- Menthol business
- Manufacturing plants
- 4 (API Units I & II — Derabassi, Punjab; Formulation Unit + Capsule Unit — Barotiwala, HP)
- API manufacturing area (Units I & II)
- ~436,000 sq. meter combined (Derabassi, Punjab)
- Export countries
- 45+
- Employees
- 2,000+
- Drug Master Filings (DMFs) filed globally
- 44
- Regulatory approvals (API facilities)
- USFDA, EU-GMP, Japan PMDA, Korea KFDA, Brazil ANVISA
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +76% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 6 | 0 | 0 | 5 | 1 | 0 | 1 | 0 |
| Expenses | 6 | 0 | 0 | 6 | 0 | 2 | 59 | 28 |
| Operating profit | -1 | 0 | 0 | -1 | 1 | -2 | -57 | -27 |
| Operating margin | −10.0% | −500.0% | −500.0% | −16.0% | 77.0% | — | −4437.0% | −6198.0% |
| Other income | 7 | 8 | -130 | -62 | -176 | 35 | -24 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 30 | 6 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Profit before tax | 5 | 8 | -130 | -64 | -176 | 3 | -88 | -24 |
| Tax rate | −2.0% | 2.0% | 0.0% | −1.0% | 0.0% | −339.0% | −22.0% | −37.0% |
| Net profit | 6 | 8 | -130 | -63 | -176 | 14 | -68 | -15 |
| EPS (₹ per share) | 0.25 | 0.35 | -5.80 | -2.82 | -7.85 | 0.64 | -3.50 | -0.79 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 1,525 | 1,685 | 365 | 7 |
| Expenses | 1,471 | 1,533 | 325 | 67 |
| Operating profit | 54 | 153 | 39 | -59 |
| Other income | 42 | 12 | -114 | -227 |
| Interest | 79 | 88 | 20 | 36 |
| Depreciation | 60 | 60 | 15 | 1 |
| Profit before tax | -42 | 18 | -112 | -325 |
| Net profit | -23 | 6 | -113 | -293 |
| Line item | Mar 2023 | Mar 2024 | Sept 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 22 | 22 | 22 | 22 | 22 | 19 |
| Reserves | 1,042 | 1,047 | 1,055 | 934 | 694 | 563 |
| Borrowings | 754 | 636 | 629 | 582 | 459 | 0 |
| Other liabilities | 371 | 486 | 476 | 509 | 639 | 39 |
| Total liabilities | 2,189 | 2,191 | 2,183 | 2,047 | 1,815 | 622 |
| Fixed assets | 662 | 643 | 804 | 633 | 28 | 105 |
| Capital work in progress | 78 | 66 | 57 | 57 | 0 | 0 |
| Investments | 1 | 1 | 1 | 1 | 1 | 13 |
| Other assets | 1,449 | 1,482 | 1,321 | 1,357 | 1,786 | 504 |
| Total assets | 2,189 | 2,191 | 2,183 | 2,047 | 1,815 | 622 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 21 | 95 | 134 | 225 | 169 | -349 |
| Cash from investing | -29 | 17 | 52 | -17 | -42 | 1,208 |
| Cash from financing | 11 | -119 | -186 | -205 | -128 | -767 |
| Net cash flow | 4 | -8 | 0 | 2 | -1 | 93 |
| Free cash flow | -10 | 110 | 183 | 195 | 126 | -341 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 89 | 98 | 67 | 82 | 76 | — |
| Inventory days | 185 | 197 | 212 | 215 | 184 | — |
| Days payable | 108 | 112 | 100 | 127 | 117 | — |
| Cash conversion cycle | 166 | 182 | 179 | 170 | 143 | — |
| Working capital days | 6 | 73 | 77 | 63 | 43 | — |
| Return on capital employed | 3.0% | 5.0% | 0.0% | 6.0% | −5.0% | 0.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Promoters hold 51.84% as of Jun 2026; institutions cut 0.10 pts since Mar 2026.
- Promoters 51.84%
- Foreign institutions 0.50%
- Domestic institutions 0.01%
- Government 3.75%
- Public 43.90%
Who is on the register
Named in the Jun 2026 filing
Every holder of Nectar Lifesciences Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 24.63% | unchanged | |
| 22.46% | unchanged | |
| 4.76% | unchanged | |
| NBFC / DFI | 3.73% | −0.28 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Nectar Lifesciences Limited
Free account: one company. Everything above stays public.
Write why you follow Nectar Lifesciences Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Nectar Lifesciences Limited
Guides on how to read this kind of business and the numbers that matter.